Humacyte (NASDAQ: HUMA)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Humacyte (NASDAQ: HUMA) through any online brokerage.
Other companies in Humacyte’s space includes: bluebird bio (NASDAQ:BLUE), Precigen (NASDAQ:PGEN), Centessa Pharmaceuticals (NASDAQ:CNTA), Eagle Pharmaceuticals (NASDAQ:EGRX) and Tango Therapeutics (NASDAQ:TNGX).
The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting HUMA to fall to within 12 months (a possible -13.42% downside). 50 analyst firms have reported ratings in the last year.
The stock price for Humacyte (NASDAQ: HUMA) is $4.62 last updated August 12, 2022, 8:00 PM UTC.
The next Humacyte (HUMA) dividend date is projected to be Thursday, September 1, 2022.
Humacyte’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Humacyte.
Humacyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.